Company Summary

OXYVITA Inc. is a biotech company that develops oxygen therapeutics and biomedical products utilizing our proprietary Zero-Link™ hemoglobin polymerization process. Our polymeric hemoglobin solution, OxyVita, is useful as a blood transfusion alternative due to its oxygen carrying function, and can dramatically reduce the need for blood donated and the risks of blood transfusions. OxyVita is intended for military and private sector use.

Team

Hanna Wollocko

President and CEO

Dr. Wollocko is a physician with specialization in internal diseases and extensive training in oncology. She has worked in hospitals, clinics and hospital blood banks, therefore being directly exposed to the need of the blood industry. She has previously owned and operated pharmaceutical contract laboratories and consulting firms. She has extensive knowledge in FDA regulation and preparation of clinical and pre-clinical studies.

John Harrington

CSO

Professor Harrington, a professor emeritus of chemistry, has been an expert in the field of acellular hemoglobin for the past 30 years. His expertise in the research on hemoglobin enables him to be the best candidate to serve as a liason between the Scientific and Medical Advisory Board and the Board of Directors. He served on the NIH's panel for the basic sciences in relation to questions still unresolved with blood substitutes.

Jacek Wollocko

COO & CIO

Mr. Wollocko has been a consultant for the pharmaceutical industry for the past 10 years. His experience in the qualification and validation of process production equipment for FDA purposes. His role at OXYVITA is process production valiidation and adherence to CFR Part 211 compliance. Mr. Wollocko has a masters degree from SUNY New Paltz in Computer Science